ArticleJournal of pain research2013
Considerations in selecting rapid-onset opioids for the management of breakthrough pain.
Article in Journal of pain research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Trial
- Establishing an efficacy hierarchy for breakthrough cancer pain management: a network meta-analysis of rapid-onset fentanyl formulations and morphine.BMC medicine · 2026Article
- Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Current management of cancer pain in Italy: Expert opinion paper.Open medicine (Warsaw, Poland) · 2022Review
- Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.Clinical drug investigation · 2016Review
- Canadian recommendations for the management of breakthrough cancer pain.Current oncology (Toronto, Ont.) · 2016Article
- Review
- Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Observational
- Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation with Pre Induction IV Fentanyl Versus Combination of IV Fentanyl and Sub Lingual Nitroglycerin Spray.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2014Article
- Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.Advances in therapy · 2014Review
- Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Considerations in selecting rapid-onset opioids for the management of breakthrough pain.Journal of pain research · 2013Article
- Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study.Pain research & managementObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthrough pain (BTP) is a transitory pain that occurs despite the use of long-term, around-the-clock analgesia. It is highly prevalent in certain populations and places a significant burden on patients, their families, caregivers, and health-care systems. Despite its prevalence and impact, BTP is sometimes unrecognized and often undertreated. Various formulations of fentanyl - a rapid-onset opioid with short duration of action - are available for the management of BTP. The efficacy of formulations using transmucosal, transbuccal, sublingual, and intranasal administration routes has been demonstrated for BTP treatment in clinical trials. However, a lack of head-to-head trials evaluating their relative efficacy makes it challenging for physicians to reach informed decisions on the most efficacious intervention for individual patients. In the absence of clear data on the relative efficacy of fentanyl formulations, prescribing decisions need to be based on physician understanding and experience and product cost and availability, taking into account the individual patient's needs, the ability of the patient or caregivers to administer medication, and the patient's wishes. This review evaluates current pharmacologic methods of alleviating BTP and discusses factors that should be considered when selecting the most appropriate formulation for individual patients. With the range of fentanyl formulations available, it is now possible to successfully address BTP in the majority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.